Lyell, Verve IPOs raise a combined $692M as both biotechs steer toward clinical trials
Lyell Immunopharma and Verve Therapeutics are still preclinical, but they're bringing novel genetic approaches to the treatment of cancer and cardiovascular disease. Now the two companies can claim two of the biggest biotech IPOs of 2021 so far.